Globiga

Globiga is a prescription‑only intravenous solution that contains human normal immunoglobulin (IgG). Marketed in the EU, its exact strength is not publicly disclosed. Administered by infusion, it provides passive immunity by supplying pooled IgG antibodies. Globiga is classified as an immunoglobulin replacement therapy and is used under medical supervision for patients with primary or secondary immunodeficiency who cannot produce sufficient antibodies and may be incorporated into individualized care plans.

Globiga is indicated for immunoglobulin replacement therapy in patients with documented antibody deficiencies.

- Primary immunodeficiency disorders such as X‑linked agammaglobulinemia, common variable immunodeficiency, and severe combined immunodeficiency. - Secondary immunodeficiency conditions resulting from chemotherapy, hematopoietic stem cell transplantation, or HIV infection. - Patients with recurrent bacterial infections despite prophylactic antibiotics. - Individuals requiring temporary immune support during periods of high infection risk, such as after major surgery or during outbreaks. - Use as part of a comprehensive management plan that includes regular monitoring of serum IgG levels.

The safety profile of Globiga reflects the typical reactions observed with intravenous immunoglobulin products, and most events are mild and transient.

Common: - Headache, fever, chills, or fatigue during or shortly after infusion. - Nausea, vomiting, or mild gastrointestinal discomfort. - Transient blood pressure changes, including mild hypertension or hypotension. - Local infusion reactions such as erythema, itching, or mild swelling at the site. - Mild muscle aches or joint pain that usually resolve without intervention.

Serious: - Severe anaphylactic or anaphylactoid reactions requiring emergency treatment. - Thromboembolic complications such as deep‑vein thrombosis, pulmonary embolism, or stroke. - Acute renal impairment or hemolytic anemia, especially in patients with pre‑existing risk factors.

When prescribing Globiga, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse events.

- Known hypersensitivity to immunoglobulin products or any component of the formulation. - History of thromboembolic disease, cardiovascular instability, or uncontrolled hypertension. - Renal impairment, especially in patients with diabetes or dehydration. - Presence of hemolytic anemia, IgA deficiency with anti‑IgA antibodies, or autoimmune disorders. - Pregnancy and lactation status should be assessed, as safety data are limited. - Concomitant use of high‑dose aspirin or other anticoagulants may increase bleeding risk. - Patients with active infections should be stabilized before initiating therapy.

Globiga may interact with other medicines or substances that affect blood viscosity, immune function, or renal clearance.

Avoid: - Concurrent administration of other intravenous immunoglobulin products or hyperimmune globulins, which can increase the total IgG load. - High‑dose aspirin or other non‑steroidal anti‑inflammatory drugs (NSAIDs) that may exacerbate bleeding tendencies.

Use with caution: - Anticoagulants such as warfarin or direct oral anticoagulants, due to potential alteration of coagulation parameters. - Diuretics and nephrotoxic agents, because of the added risk of renal impairment. - Live vaccines, as passive antibodies may interfere with vaccine efficacy. - Corticosteroids, which may mask early signs of infection during therapy.